Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Analogue-based drug discovery [[electronic resource] /] / János Fischer, C. Robin Ganellin
| Analogue-based drug discovery [[electronic resource] /] / János Fischer, C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim ; ; [Chichester], : Wiley-VCH, c2006 |
| Descrizione fisica | 1 online resource (609 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Pharmacology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-72276-2
9786610722761 3-527-60800-1 3-527-60749-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery; Contents; Preface; Introduction; List of Contributors; Abbreviations; Part I General Aspects of Analogue-Based Drug Discovery; 1 Analogues as a Means of Discovering New Drugs; 1.1 Designing of Analogues; 1.1.1 Analogues Produced by Homologous Variations; 1.1.1.1 Homology Through Monoalkylation; 1.1.1.2 Polymethylenic Bis-Ammonium Compounds: Hexa- and Decamethonium; 1.1.1.3 Homology in Cyclic Compounds; 1.1.2 Analogues Produced by Vinylogy; 1.1.2.1 Zaprinast Benzologues; 1.1.3 Analogues Produced by Isosteric Variations
1.1.3.1 The Dominant Parameter is Structural1.1.3.2 The Dominant Parameter is Electronic; 1.1.3.3 The Dominant Parameter is Lipophilicity; 1.1.4 Positional Isomers Produced as Analogues; 1.1.5 Optical Isomers Produced as Analogues; 1.1.5.1 Racemic Switches; 1.1.5.2 Specific Profile for Each Enantiomer; 1.1.6 Analogues Produced by Ring Transformations; 1.1.7 Twin Drugs; 1.2 The Pros and Cons of Analogue Design; 1.2.1 The Success is Almost Warranted; 1.2.2 The Information is Available; 1.2.3 Financial Considerations; 1.2.4 Emergence of New Properties 1.3 Analogue Design as a Means of Discovering New Drugs1.3.1 New Uses for Old Drugs; 1.3.2 The PASS Program; 1.3.3 New Leads from Old Drugs: The SOSA Approach; 1.3.3.1 Definition; 1.3.3.2 Rationale; 1.3.3.3 Availability; 1.3.3.4 Examples; 1.3.3.4 Discussion; 1.4 Conclusion; 2 Drug Likeness and Analogue-Based Drug Discovery; 3 Privileged Structures and Analogue-Based Drug Discovery; 3.1 Introduction; 3.2 Drugs from Side Effects; 3.3 Agonists and Antagonists; 3.4 Privileged Structures; 3.5 Drug Action on Target Classes; 3.5.1 GPCR Ligands; 3.5.2 Nuclear Receptor Ligands; 3.5.3 Integrin Ligands 3.5.4 Kinase Inhibitors3.5.5 Phosphodiesterase Inhibitors; 3.5.6 Neurotransmitter Uptake Inhibitors; 3.6 Summary and Conclusions; Part II Selected Examples of Analogue-Based Drug Discoveries; 1 Development of Anti-Ulcer H(2)-Receptor Histamine Antagonists; 1.1 Introduction; 1.2 The Prototype Drug, Burimamide, Defined Histamine H(2)-Receptors; 1.3 The Pioneer Drug, Cimetidine: A Breakthrough for Treating Peptic Ulcer Disease; 1.4 Ranitidine: The First Successful Analogue of H(2) Antagonists; 1.5 The Discovery of Tiotidine and Famotidine; 1.6 Other Compounds 1.7 The Use of H(2)-Receptor Histamine Antagonists as Medicines2 Esomeprazole in the Framework of Proton-Pump Inhibitor Development; 2.1 Towards Omeprazole: The First Proton-Pump Inhibitor; 2.2 The Treatment of Acid-Related Disorders Before Losec®; 2.3 Pioneer Research at Hässle during the 1960s and 1970s; 2.3.1 Toxicological Challenges; 2.3.2 Discovery of H(+), K(+)-ATPase: The Gastric Proton Pump; 2.3.3 Analogue Optimization; 2.4 The Development of Omeprazole; 2.4.1 Further Toxicological Challenges and the Halt of the Clinical Program; 2.4.2 Resumption of Clinical Studies 2.4.3 Omeprazole Reaches the Market and Supersedes H(2)-Receptor Antagonists |
| Record Nr. | UNINA-9910144274903321 |
| Weinheim ; ; [Chichester], : Wiley-VCH, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery / / Janos Fischer, C. Robin Ganellin
| Analogue-based drug discovery / / Janos Fischer, C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim ; ; [Chichester], : Wiley-VCH, c2006 |
| Descrizione fisica | 1 online resource (609 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJanos
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Pharmacology |
| ISBN |
1-280-72276-2
9786610722761 3-527-60800-1 3-527-60749-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery; Contents; Preface; Introduction; List of Contributors; Abbreviations; Part I General Aspects of Analogue-Based Drug Discovery; 1 Analogues as a Means of Discovering New Drugs; 1.1 Designing of Analogues; 1.1.1 Analogues Produced by Homologous Variations; 1.1.1.1 Homology Through Monoalkylation; 1.1.1.2 Polymethylenic Bis-Ammonium Compounds: Hexa- and Decamethonium; 1.1.1.3 Homology in Cyclic Compounds; 1.1.2 Analogues Produced by Vinylogy; 1.1.2.1 Zaprinast Benzologues; 1.1.3 Analogues Produced by Isosteric Variations
1.1.3.1 The Dominant Parameter is Structural1.1.3.2 The Dominant Parameter is Electronic; 1.1.3.3 The Dominant Parameter is Lipophilicity; 1.1.4 Positional Isomers Produced as Analogues; 1.1.5 Optical Isomers Produced as Analogues; 1.1.5.1 Racemic Switches; 1.1.5.2 Specific Profile for Each Enantiomer; 1.1.6 Analogues Produced by Ring Transformations; 1.1.7 Twin Drugs; 1.2 The Pros and Cons of Analogue Design; 1.2.1 The Success is Almost Warranted; 1.2.2 The Information is Available; 1.2.3 Financial Considerations; 1.2.4 Emergence of New Properties 1.3 Analogue Design as a Means of Discovering New Drugs1.3.1 New Uses for Old Drugs; 1.3.2 The PASS Program; 1.3.3 New Leads from Old Drugs: The SOSA Approach; 1.3.3.1 Definition; 1.3.3.2 Rationale; 1.3.3.3 Availability; 1.3.3.4 Examples; 1.3.3.4 Discussion; 1.4 Conclusion; 2 Drug Likeness and Analogue-Based Drug Discovery; 3 Privileged Structures and Analogue-Based Drug Discovery; 3.1 Introduction; 3.2 Drugs from Side Effects; 3.3 Agonists and Antagonists; 3.4 Privileged Structures; 3.5 Drug Action on Target Classes; 3.5.1 GPCR Ligands; 3.5.2 Nuclear Receptor Ligands; 3.5.3 Integrin Ligands 3.5.4 Kinase Inhibitors3.5.5 Phosphodiesterase Inhibitors; 3.5.6 Neurotransmitter Uptake Inhibitors; 3.6 Summary and Conclusions; Part II Selected Examples of Analogue-Based Drug Discoveries; 1 Development of Anti-Ulcer H(2)-Receptor Histamine Antagonists; 1.1 Introduction; 1.2 The Prototype Drug, Burimamide, Defined Histamine H(2)-Receptors; 1.3 The Pioneer Drug, Cimetidine: A Breakthrough for Treating Peptic Ulcer Disease; 1.4 Ranitidine: The First Successful Analogue of H(2) Antagonists; 1.5 The Discovery of Tiotidine and Famotidine; 1.6 Other Compounds 1.7 The Use of H(2)-Receptor Histamine Antagonists as Medicines2 Esomeprazole in the Framework of Proton-Pump Inhibitor Development; 2.1 Towards Omeprazole: The First Proton-Pump Inhibitor; 2.2 The Treatment of Acid-Related Disorders Before Losec®; 2.3 Pioneer Research at Hässle during the 1960s and 1970s; 2.3.1 Toxicological Challenges; 2.3.2 Discovery of H(+), K(+)-ATPase: The Gastric Proton Pump; 2.3.3 Analogue Optimization; 2.4 The Development of Omeprazole; 2.4.1 Further Toxicological Challenges and the Halt of the Clinical Program; 2.4.2 Resumption of Clinical Studies 2.4.3 Omeprazole Reaches the Market and Supersedes H(2)-Receptor Antagonists |
| Record Nr. | UNINA-9910877327603321 |
| Weinheim ; ; [Chichester], : Wiley-VCH, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| Soggetto genere / forma | Electronic books. |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910140756503321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II [[electronic resource] /] / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910830524603321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery II / / edited by Janos Fischer and C. Robin Ganellin
| Analogue-based drug discovery II / / edited by Janos Fischer and C. Robin Ganellin |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2010 |
| Descrizione fisica | 1 online resource (566 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJanos
GanellinC. R (C. Robin) |
| Soggetto topico |
Drug development
Drugs - Design |
| ISBN |
3-527-63212-3
1-282-78383-1 9786612783838 3-527-63003-1 3-527-63004-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs
9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index |
| Record Nr. | UNINA-9910877334703321 |
| Weinheim, : Wiley-VCH, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery III [[electronic resource] /] / edited by János Fischer, C. Robin Ganellin and David P. Rotella
| Analogue-based drug discovery III [[electronic resource] /] / edited by János Fischer, C. Robin Ganellin and David P. Rotella |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2013 |
| Descrizione fisica | 1 online resource (405 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) RotellaDavid P |
| Soggetto topico | Drug development |
| ISBN |
3-527-65108-X
1-299-24120-4 3-527-65111-X 3-527-65110-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. General aspects -- pt. 2. Drug classes -- pt. 3. Case studies. |
| Record Nr. | UNINA-9910141647903321 |
| Weinheim, Germany, : Wiley-VCH, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analogue-based drug discovery III / / edited by János Fischer, C. Robin Ganellin and David P. Rotella
| Analogue-based drug discovery III / / edited by János Fischer, C. Robin Ganellin and David P. Rotella |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2013 |
| Descrizione fisica | 1 online resource (405 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
FischerJános
GanellinC. R (C. Robin) RotellaDavid P |
| Soggetto topico | Drug development |
| ISBN |
3-527-65108-X
1-299-24120-4 3-527-65111-X 3-527-65110-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. General aspects -- pt. 2. Drug classes -- pt. 3. Case studies. |
| Record Nr. | UNINA-9910822629203321 |
| Weinheim, Germany, : Wiley-VCH, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Introduction to biological and small molecule drug research and development : theory and case studies / / edited by Robin Ganellin, Stanley Roberts, Roy Jefferis
| Introduction to biological and small molecule drug research and development : theory and case studies / / edited by Robin Ganellin, Stanley Roberts, Roy Jefferis |
| Pubbl/distr/stampa | Waltham, Mass., : Elsevier, 2013 |
| Descrizione fisica | 1 online resource (xx, 425 pages, 21 unnumbered pages of plates) : illustrations (some color) |
| Disciplina | 610.72 |
| Collana | Gale eBooks |
| Soggetto topico |
Drug development
Biopharmaceutics |
| ISBN | 0-12-397770-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies; Copyright; Contents; Biographies; Preface; Chapter 1 - Introduction to enzymes, receptors and the action of small molecule drugs; 1.1 SECTION I: BACKGROUND INFORMATION; 1.2 SECTION II: MORE ABOUT ENZYMES; 1.3 SECTION III: MORE ABOUT RECEPTORS; 1.4 SECTION IV; Further Reading; Chapter 2 - Protein structure and function; 2.1 INTRODUCTION; 2.2 GENERAL ASPECTS OF PROTEIN STRUCTURE; 2.3 ENZYMES; 2.4 PROTEIN RECEPTORS; 2.5 STRUCTURAL PROTEINS AS DRUG TARGETS; 2.6 PROTEINS AS DRUGS
2.7 CONCLUDING REMARKSReferences; Chapter 3 - The small molecule drug discovery process - from target selection to candidate selection; 3.1 INTRODUCTION; 3.2 WHERE DO LEADS COME FROM?; 3.3 LEAD GENERATION: ACTIVE-TO-HIT; 3.4 LEAD GENERATION: HIT-TO-LEAD; 3.5 LO - ESTABLISHING THE SCREENING CASCADE AND CANDIDATE BIOLOGICAL TARGET PROFILE; References and Notes; Further Reading; Chapter 4 - Protein therapeutics (introduction to biopharmaceuticals); 4.1 INTRODUCTION; 4.2 TYPES OF PROTEIN THERAPEUTICS I: REGULATORY AND ENZYMATIC ACTIVITY; 4.3 TYPES OF PROTEIN THERAPEUTICS II: TARGETING ACTIVITY 4.4 CHALLENGES OF PROTEIN THERAPEUTICS4.5 FUTURE DIRECTIONS FOR PROTEIN THERAPEUTICS; 4.6 BIOSIMILAR PROTEIN THERAPEUTICS; 4.7 SUMMARY AND CONCLUSIONS; References; Further Reading; Chapter 5 - Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics; 5.1 INTRODUCTION; 5.2 HOW DO SMDS DIFFER FROM BIOMOLECULAR DRUGS?; 5.3 HISTORICAL CHANGES TO THE FDA APPROACH TO HANDLE THE BIOTECH BOOM-THE DIFFERING NOMENCLATURE FOR SMALL MOLECULES VS BIOLOGI ...; 5.4 COMPARISONS OF CLINICAL METRICS-BIOLOGICS VS SMALL MOLECULES 5.5 ARE PEPTIDE DRUGS SMALL MOLECULES OR BIOLOGICS?5.6 THE MANUFACTURE AND SUPPLY OF SMDS VS BIOMOLECULAR DRUGS; 5.7 THE PRICING OF SMDS VS BIOMOLECULAR DRUGS; 5.8 COMPARING SMALL-MOLECULE, PEPTIDE AND BIOMOLECULAR DRUGS IN THE MARKET; 5.9 BIOSIMILAR BIOMOLECULES VS GENERIC SMALL MOLECULES; 5.10 DISCOVERY AND PRECLINICAL STAGES FOR SMDS VS BIOMOLECULAR DRUGS-WHERE THE TECHNOLOGIES DIFFER THE MOST; 5.11 SMALL-MOLECULE AND BIOLOGICS APPROVALS BY THERAPY AREAS; 5.12 MANAGING SMALL-MOLECULE & BIOMOLECULAR DRUG R&D IN THE SAME COMPANY; 5.13 CONCLUSION; References Chapter 6 - Therapies for type 2 diabetes: modulating the incretin pathway using small molecule peptidase inhibitors or pep ...6.1 INTRODUCTION; 6.2 PHARMACOTHERAPY OF TYPE 2 DIABETES; 6.3 THE RATIONALE FOR INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES; 6.4 DISCOVERY AND PHARMACOKINETICS OF THE INCRETIN-BASED THERAPIES; 6.5 CLINICAL EFFICACY OF THE INCRETIN-BASED THERAPIES; 6.6 EVIDENCE FOR DISEASE MODIFICATION; 6.7 IMPACT ON CARDIOVASCULAR RISK; 6.8 CLINICAL SAFETY AND TOLERABILITY OF INCRETIN-BASED THERAPIES; 6.9 CONCLUSIONS; References Chapter 7 - The structure and business of biopharmaceutical companies including the management of risks and resources |
| Record Nr. | UNINA-9910792478903321 |
| Waltham, Mass., : Elsevier, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Introduction to biological and small molecule drug research and development : theory and case studies / / edited by Robin Ganellin, Stanley Roberts, Roy Jefferis
| Introduction to biological and small molecule drug research and development : theory and case studies / / edited by Robin Ganellin, Stanley Roberts, Roy Jefferis |
| Pubbl/distr/stampa | Waltham, Mass., : Elsevier, 2013 |
| Descrizione fisica | 1 online resource (xx, 425 pages, 21 unnumbered pages of plates) : illustrations (some color) |
| Disciplina | 610.72 |
| Collana | Gale eBooks |
| Soggetto topico |
Drug development
Biopharmaceutics |
| ISBN | 0-12-397770-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies; Copyright; Contents; Biographies; Preface; Chapter 1 - Introduction to enzymes, receptors and the action of small molecule drugs; 1.1 SECTION I: BACKGROUND INFORMATION; 1.2 SECTION II: MORE ABOUT ENZYMES; 1.3 SECTION III: MORE ABOUT RECEPTORS; 1.4 SECTION IV; Further Reading; Chapter 2 - Protein structure and function; 2.1 INTRODUCTION; 2.2 GENERAL ASPECTS OF PROTEIN STRUCTURE; 2.3 ENZYMES; 2.4 PROTEIN RECEPTORS; 2.5 STRUCTURAL PROTEINS AS DRUG TARGETS; 2.6 PROTEINS AS DRUGS
2.7 CONCLUDING REMARKSReferences; Chapter 3 - The small molecule drug discovery process - from target selection to candidate selection; 3.1 INTRODUCTION; 3.2 WHERE DO LEADS COME FROM?; 3.3 LEAD GENERATION: ACTIVE-TO-HIT; 3.4 LEAD GENERATION: HIT-TO-LEAD; 3.5 LO - ESTABLISHING THE SCREENING CASCADE AND CANDIDATE BIOLOGICAL TARGET PROFILE; References and Notes; Further Reading; Chapter 4 - Protein therapeutics (introduction to biopharmaceuticals); 4.1 INTRODUCTION; 4.2 TYPES OF PROTEIN THERAPEUTICS I: REGULATORY AND ENZYMATIC ACTIVITY; 4.3 TYPES OF PROTEIN THERAPEUTICS II: TARGETING ACTIVITY 4.4 CHALLENGES OF PROTEIN THERAPEUTICS4.5 FUTURE DIRECTIONS FOR PROTEIN THERAPEUTICS; 4.6 BIOSIMILAR PROTEIN THERAPEUTICS; 4.7 SUMMARY AND CONCLUSIONS; References; Further Reading; Chapter 5 - Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics; 5.1 INTRODUCTION; 5.2 HOW DO SMDS DIFFER FROM BIOMOLECULAR DRUGS?; 5.3 HISTORICAL CHANGES TO THE FDA APPROACH TO HANDLE THE BIOTECH BOOM-THE DIFFERING NOMENCLATURE FOR SMALL MOLECULES VS BIOLOGI ...; 5.4 COMPARISONS OF CLINICAL METRICS-BIOLOGICS VS SMALL MOLECULES 5.5 ARE PEPTIDE DRUGS SMALL MOLECULES OR BIOLOGICS?5.6 THE MANUFACTURE AND SUPPLY OF SMDS VS BIOMOLECULAR DRUGS; 5.7 THE PRICING OF SMDS VS BIOMOLECULAR DRUGS; 5.8 COMPARING SMALL-MOLECULE, PEPTIDE AND BIOMOLECULAR DRUGS IN THE MARKET; 5.9 BIOSIMILAR BIOMOLECULES VS GENERIC SMALL MOLECULES; 5.10 DISCOVERY AND PRECLINICAL STAGES FOR SMDS VS BIOMOLECULAR DRUGS-WHERE THE TECHNOLOGIES DIFFER THE MOST; 5.11 SMALL-MOLECULE AND BIOLOGICS APPROVALS BY THERAPY AREAS; 5.12 MANAGING SMALL-MOLECULE & BIOMOLECULAR DRUG R&D IN THE SAME COMPANY; 5.13 CONCLUSION; References Chapter 6 - Therapies for type 2 diabetes: modulating the incretin pathway using small molecule peptidase inhibitors or pep ...6.1 INTRODUCTION; 6.2 PHARMACOTHERAPY OF TYPE 2 DIABETES; 6.3 THE RATIONALE FOR INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES; 6.4 DISCOVERY AND PHARMACOKINETICS OF THE INCRETIN-BASED THERAPIES; 6.5 CLINICAL EFFICACY OF THE INCRETIN-BASED THERAPIES; 6.6 EVIDENCE FOR DISEASE MODIFICATION; 6.7 IMPACT ON CARDIOVASCULAR RISK; 6.8 CLINICAL SAFETY AND TOLERABILITY OF INCRETIN-BASED THERAPIES; 6.9 CONCLUSIONS; References Chapter 7 - The structure and business of biopharmaceutical companies including the management of risks and resources |
| Record Nr. | UNINA-9910808755803321 |
| Waltham, Mass., : Elsevier, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||